Chronic	chronic	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
novel	novel	O	O	O	O
synthetic	synthetic	O	O	O	O
anthracycline	anthracycline	CHEMICALS	O	OTHERS	I
derivative	derivative	O	O	O	O
(	(	O	O	O	O
SM-5887	sm-5887	O	O	OTHERS	I
)	)	O	O	O	O
on	on	O	O	O	O
normal	normal	O	O	O	O
heart	heart	O	O	O	O
and	and	O	O	O	O
doxorubicin-induced	doxorubicin-induced	O	O	O	O
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
in	in	O	O	O	O
beagle	beagle	O	O	O	O
dogs	dogs	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
designed	designed	O	O	O	O
to	to	O	O	O	O
investigate	investigate	O	O	O	O
the	the	O	O	O	O
chronic	chronic	O	O	O	O
cardiotoxic	cardiotoxic	O	DISEASE	OTHERS	I
potential	potential	O	O	O	O
of	of	O	O	O	O
SM-5887	sm-5887	O	O	OTHERS	I
and	and	O	O	O	O
a	a	O	O	O	O
possible	possible	O	O	O	O
deteriorating	deteriorating	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
SM-5887	sm-5887	O	O	OTHERS	I
on	on	O	O	O	O
low-grade	low-grade	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
pre-induced	pre-induced	O	O	O	O
by	by	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
beagle	beagle	O	O	O	O
dogs	dogs	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
chronic	chronic	O	O	O	O
treatment	treatment	O	O	O	O
,	,	O	O	O	O
beagle	beagle	O	O	O	O
dogs	dogs	O	O	O	O
of	of	O	O	O	O
each	each	O	O	O	O
sex	sex	O	O	O	O
were	were	O	O	O	O
given	given	O	O	O	O
intravenously	intravenously	O	O	O	O
once	once	O	O	O	O
every	every	O	O	O	O
3	3	O	O	O	O
weeks	weeks	O	O	O	O
,	,	O	O	O	O
either	either	O	O	O	O
a	a	O	O	O	O
sublethal	sublethal	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1.5	1.5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
SM-5887	sm-5887	O	O	OTHERS	I
(	(	O	O	O	O
2.5	2.5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
experiment	experiment	O	O	O	O
was	was	O	O	O	O
terminated	terminated	O	O	O	O
3	3	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
ninth	ninth	O	O	O	O
dosing	dosing	O	O	O	O
.	.	O	O	O	O

Animals	animals	O	O	O	O
which	which	O	O	O	O
received	received	O	O	O	O
over	over	O	O	O	O
six	six	O	O	O	O
courses	courses	O	O	O	O
of	of	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
demonstrated	demonstrated	O	O	O	O
the	the	O	O	O	O
electrocardiogram	electrocardiogram	O	O	O	O
(	(	O	O	O	O
ECG	ecg	O	O	O	O
)	)	O	O	O	O
changes	changes	O	O	O	O
,	,	O	O	O	O
decrease	decrease	O	O	O	O
of	of	O	O	O	O
blood	blood	O	O	O	O
pressure	pressure	O	O	O	O
and	and	O	O	O	O
high-grade	high-grade	O	O	O	O
histopathological	histopathological	O	O	O	O
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
,	,	O	O	O	O
while	while	O	O	O	O
animals	animals	O	O	O	O
which	which	O	O	O	O
were	were	O	O	O	O
terminally	terminally	O	O	O	O
sacrificed	sacrificed	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
SM-5887	sm-5887	O	O	OTHERS	I
administration	administration	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
show	show	O	O	O	O
any	any	O	O	O	O
changes	changes	O	O	O	O
in	in	O	O	O	O
ECG	ecg	O	O	O	O
,	,	O	O	O	O
blood	blood	O	O	O	O
pressure	pressure	O	O	O	O
and	and	O	O	O	O
histopathological	histopathological	O	O	O	O
examinations	examinations	O	O	O	O
.	.	O	O	O	O

To	to	O	O	O	O
examine	examine	O	O	O	O
a	a	O	O	O	O
possibly	possibly	O	O	O	O
deteriorating	deteriorating	O	O	O	O
cardiotoxic	cardiotoxic	O	DISEASE	OTHERS	I
effect	effect	O	O	O	O
of	of	O	O	O	O
SM-5887	sm-5887	O	O	OTHERS	I
,	,	O	O	O	O
low-grade	low-grade	O	O	O	O
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
was	was	O	O	O	O
induced	induced	O	O	O	O
in	in	O	O	O	O
dogs	dogs	O	O	O	O
by	by	O	O	O	O
four	four	O	O	O	O
courses	courses	O	O	O	O
of	of	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1.5	1.5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Nine	nine	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
pre-treatment	pre-treatment	O	O	O	O
,	,	O	O	O	O
dogs	dogs	O	O	O	O
were	were	O	O	O	O
given	given	O	O	O	O
four	four	O	O	O	O
courses	courses	O	O	O	O
of	of	O	O	O	O
either	either	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1.5	1.5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
SM-5887	sm-5887	O	O	OTHERS	I
(	(	O	O	O	O
2.5	2.5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
once	once	O	O	O	O
every	every	O	O	O	O
3	3	O	O	O	O
weeks	weeks	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
low-grade	low-grade	O	O	O	O
cardiotoxic	cardiotoxic	O	DISEASE	OTHERS	I
changes	changes	O	O	O	O
were	were	O	O	O	O
enhanced	enhanced	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
additional	additional	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
.	.	O	O	O	O

On	on	O	O	O	O
the	the	O	O	O	O
contrary	contrary	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
SM-5887	sm-5887	O	O	OTHERS	I
treatment	treatment	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
progress	progress	O	O	O	O
the	the	O	O	O	O
grade	grade	O	O	O	O
of	of	O	O	O	O
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
conclusion	conclusion	O	O	O	O
,	,	O	O	O	O
SM-5887	sm-5887	O	O	OTHERS	I
does	does	O	O	O	O
not	not	O	O	O	O
have	have	O	O	O	O
any	any	O	O	O	O
potential	potential	O	O	O	O
of	of	O	O	O	O
chronic	chronic	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
and	and	O	O	O	O
deteriorating	deteriorating	O	O	O	O
effect	effect	O	O	O	O
on	on	O	O	O	O
doxorubicin-induced	doxorubicin-induced	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
dogs	dogs	O	O	O	O
.	.	O	O	O	O

